How to Build a QA Process for a Healthcare Platform Operating Across Multiple Markets

A healthcare technology platform operating without formal quality assurance is not just carrying technical risk, it is carrying patient trust risk, and in a regulated, patient-facing industry, those two things are inseparable.

For digital health companies scaling across multiple markets and languages, the absence of a structured QA function creates a specific and compounding exposure: defects accumulate silently across the product portfolio, invisible to teams without the tools or process to detect them systematically. When those defects surface in production, in a clinical context, for a user seeking care, the consequences extend well beyond a typical software quality incident. They affect the user relationships and institutional trust that digital healthcare businesses depend on for long-term viability.

This article addresses the practical question facing healthcare technology leaders who have recognized this risk: what does it actually take to build a formal QA process from scratch for a multi-product, multi-market health platform—and how should it be structured to deliver value immediately while scaling with the product?

It draws on TestDevLab's engagement with Doktor.se, one of Sweden's largest providers of digital healthcare, operating physical clinics across Sweden alongside digital services that reach patients worldwide. Prior to engaging TestDevLab, Doktor.se had no formal quality assurance process in place. Read the full Doktor.se case study for complete details on the engagement and outcomes.

Why is the absence of formal QA particularly dangerous in healthcare technology?

Every software product that ships without adequate quality assurance carries risk. In healthcare technology, that risk has a distinctive structure.

Healthcare platforms are trust-dependent at a fundamental level. A patient using a digital health service is making a decision about their care, and the reliability of the platform is a prerequisite for that decision to go well. A bug that produces incorrect information, an interface failure that prevents a consultation from completing, or a defect that causes a referral to be lost are not abstract quality incidents. They are failures in a system the patient trusted with something that matters.

This trust dependency also creates a reputational asymmetry. In most software categories, users tolerate defects with some degree of resilience. In healthcare, the same defect carries a higher reputational cost. This is because the expectation of reliability is higher, and the consequences of a failure are more personal. A healthcare platform that loses user trust due to quality failures faces remediation costs that extend well beyond the technical fix.

The regulatory dimension compounds this further. Healthcare technology businesses operating across multiple markets face regulatory environments that, in some jurisdictions, treat software quality as a compliance requirement, not just a product decision. QA infrastructure that cannot demonstrate systematic, documented testing coverage is a liability in these environments.

Finally, multi-market and multi-language deployment multiplies the defect surface area in ways that single-market testing cannot adequately cover. A defect that only manifests in one language configuration, or only in one market's regulatory context, will not be caught by testing that does not extend across the full deployment matrix.

What specific QA challenges do multi-product, multi-market health platforms face?

Healthcare platforms that have grown without formal QA infrastructure tend to accumulate quality risk in predictable patterns.

• Informal quality checks that cannot scale. Engineering teams without dedicated QA resources rely on developer testing and informal review processes. These approaches catch some defects in the features being actively developed, but they are not systematic, not repeatable, and not designed to validate the behavior of the product as experienced by a user. As the product grows, the proportion of the product covered by these checks decreases.
• No regression coverage across the product portfolio. Without defined testing procedures and a regression suite, every release carries unquantified risk to existing functionality. There is no systematic way to verify that new development has not broken something that previously worked — and in a platform with multiple products across multiple markets, the regression surface area is large.
• Quality issues that are invisible until they reach users. Defects that an informal process does not catch do not disappear, they accumulate in the released product and surface when users encounter them. In a healthcare context, user-reported defects carry a higher remediation cost and a higher reputational cost than defects caught in testing.
• No structured mechanism for feeding defect data back to development. Without consistent testing procedures and standardized reporting, the information available to engineering and product teams about the quality state of the product is incomplete and unstructured. Development priorities are not informed by systematic defect data, and quality improvements are reactive rather than planned.

What does a well-structured QA implementation look like for a health platform?

The structural principle that drives effective QA implementation in this context is embedding, positioning QA as an ongoing discipline integrated into the development workflow, rather than a post-development audit layer that reviews work after the fact.

• Begin with a structured pilot. A time-bounded pilot project that tests and validates the product against defined specifications serves two purposes simultaneously: it establishes the scope of existing quality issues, and it demonstrates the QA team's ability to address them systematically. A successful pilot provides the evidence base for expanding QA coverage across the full product portfolio.
• Establish testing procedures and best practices from scratch. The foundational work of defining what will be tested, how it will be tested, and what constitutes a passing result is the prerequisite for everything that follows. Without this procedural foundation, testing activity is not repeatable, not comparable across products or markets, and not structured to improve over time.
• Cover mobile and web surfaces across all market configurations. Multi-product, multi-market platforms require testing coverage that reflects the diversity of the actual user base, not a sample of it. For a platform deployed across five languages and multiple international markets, testing that does not extend across all market and language configurations will systematically miss defects that only manifest in specific configurations.
• Embed QA participation in day-to-day development activity. When QA engineers participate in sprint planning and development activities alongside engineering and product teams, quality becomes an input to development decisions rather than a checkpoint after them. This integration changes how the development team approaches quality, from a post-development concern to an ongoing consideration embedded in how work is planned and executed.
• Deliver structured defect reporting that drives development decisions. The value of testing is realized when defect data informs prioritization. Reporting that provides structured, actionable information about what was found, why it matters, and how to reproduce it gives engineering and product teams what they need to address quality issues efficiently.

What did structured QA implementation reveal at a real digital healthcare company?

Doktor.se's engagement with TestDevLab illustrates the gap between what informal quality processes can detect and what structured, systematic testing finds.

The pilot phase alone surfaced over 100 previously undetected issues—defects that had remained invisible to the engineering team's informal quality checks. In a trust-sensitive, patient-facing context, these were not abstract bugs. Left unaddressed, they represented risk of user drop-off, reputational harm, and significantly higher remediation costs if discovered in production rather than in testing.

The absence of any QA process had created compounding risk across the product portfolio. Because Doktor.se operated without defined testing procedures, there were no consistent standards for quality assessment, no repeatable regression coverage, and no structured mechanism for feeding defect data back to development. The engagement addressed all three gaps simultaneously.

Embedding TestDevLab's QA team in day-to-day activities, rather than operating as a separate review layer, changed how quality was managed across the organization. Real-time input from a QA perspective during sprint planning positioned quality as an ongoing discipline rather than a post-development checkpoint.

Multi-market, multi-language coverage across five languages and seven products revealed issues that single-market testing would not have caught. Specifically, defects that only manifested in specific language or market configurations, and would have reached users in those markets undetected without systematic cross-market validation.

Following a successful pilot, the collaboration expanded into a formal contract, with the QA team embedded across all seven of Doktor.se's products and continuing to participate in day-to-day engineering and product activities.

Read the full Doktor.se case study for the complete scope, methodology, and findings.

The bottom line

For healthcare technology companies operating across multiple products, markets, and languages, the cost of deferred QA is measured not just in technical debt but in patient trust risk. And the structured pilot, embedded team, and multi-market coverage model that addresses it compounds in value with every release cycle.